MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Regulus Therapeutics Company Profile (NASDAQ:RGLS)

Consensus Ratings for Regulus Therapeutics (NASDAQ:RGLS) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.20 (376.37% upside)

Analysts' Ratings History for Regulus Therapeutics (NASDAQ:RGLS)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016WedbushReiterated RatingOutperform$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Needham & Company LLCReiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Chardan CapitalBoost Price TargetBuy$15.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016FBR & Co.Reiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016BMO Capital MarketsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Wells FargoInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2015GuggenheimInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Deutsche BankSet Price TargetBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Regulus Therapeutics (NASDAQ:RGLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/2/2016Q1($0.33)($0.40)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2016Q415($0.25)($0.14)$5.09 million$10.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.37)($0.25)$2.85 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.29)($0.41)$2.40 million$3.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.26)($0.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015($0.21)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014($0.23)($0.23)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.19)($0.29)$3.19 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.14)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014($0.13)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/19/2012Q312($15.98)$3.81 million$2.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Regulus Therapeutics (NASDAQ:RGLS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.33)($0.32)($0.33)
Q2 20162($0.42)($0.32)($0.37)
Q3 20162($0.44)($0.32)($0.38)
Q4 20162($0.45)($0.32)($0.39)
(Data provided by Zacks Investment Research)
Dividend History for Regulus Therapeutics (NASDAQ:RGLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Regulus Therapeutics (NASDAQ:RGLS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Regulus Therapeutics (NASDAQ:RGLS)
DateHeadline
06/24/16 08:43 AMCovering the Bases on Regulus Therapeutics Inc. (NASDAQ:RGLS): Where is the Stock Going? - Press Telegraph
06/23/16 06:44 PMBrokers Issue Average Price Target Of 23.46 On Regulus Therapeutics Inc. (RGLS) - Fiscal Standard
06/23/16 06:44 PMStrong Sell Calls Recommendations For Regulus Therapeutics Inc. (NASDAQ:RGLS) At 0 - Investor Newswire
06/23/16 03:02 PMREGULUS THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ -
06/22/16 06:05 PMRegulus Therapeutics Inc. (RGLS) Updated Price Targets - FTSE News
06/22/16 06:05 PMRegulus Therapeutics Inc. (NasdaqGM:RGLS) Stock Momentum Hits EXTREME Weakness - CML News
06/20/16 05:52 PMRegulus Therapeutics Secures $30 Million Credit Facility
06/20/16 05:52 PMSoCal’s Regulus Locks in $30 Million
06/20/16 05:52 PMRegulus Secures $30 Million Growth Capital Credit Facility
06/20/16 07:40 AMRegulus Therapeutics Inc. (RGLS) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 08:50 AMStrong Buy Calls Count For Regulus Therapeutics Inc. (NASDAQ:RGLS) At 6 - Investor Newswire
06/17/16 08:50 AMRegulus Therapeutics Inc. (RGLS) Jumps 6.37% on June 15 - Equities.com
06/17/16 08:50 AMFloating Price Update: Select Medical Holdings Corporation (NYSE:SEM) , Regulus Therapeutics Inc. (NASDAQ:RGLS) - Street Updates
06/14/16 03:33 PMREGULUS THERAPEUTICS INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders -
06/14/16 10:52 AMChardan Capital Maintains Regulus Therapeutics Inc to Buy with Price Target $20.00 - TheFounders Daily
06/14/16 10:52 AMPrice Trends to Watch: Regulus Therapeutics Inc. (NASDAQ:RGLS) , Cerus Corporation (NASDAQ:CERS) - Street Updates
06/10/16 09:07 AMRegulus Therapeutics Inc. (RGLS) is Trading Lower on Unusual Volume for June 08 - Equities.com
06/09/16 06:34 PMInvestors Attention Alert: Regulus Therapeutics Inc. (NASDAQ:RGLS) , Cerus Corporation (NASDAQ:CERS) - Street Updates
06/08/16 06:37 PMStock Analysis review: Regulus Therapeutics Inc. (NASDAQ:RGLS) - News Oracle
06/08/16 06:37 PMWill You Buy These Stocks? Regulus Therapeutics Inc. (NASDAQ:RGLS), 3D Systems Corporation (NYSE:DDD) - Beacon Chronicle
06/08/16 06:37 PMRegulus Therapeutics Inc. (RGLS) Drops 8.08% on June 07 - Equities.com
06/08/16 06:37 PMREGULUS THERAPEUTICS INC. (NASDAQ:RGLS) Financial Condition Compared to S&P 500 - CML News
06/08/16 03:02 PMREGULUS THERAPEUTICS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submis -
06/07/16 06:21 PMRegulus Therapeutics Inc (RGLS) Stock Rises on Phase II RG-101 Top-Line Results - Bidness ETC
06/07/16 08:52 AM12 Stocks Moving In Tuesday's Pre-Market Session
06/07/16 08:52 AMRegulus Reports Positive Top-line Data
06/07/16 07:34 AMRegulus Reveals Positive Top-line Data On Hepatitis C Virus Treatment - Regulus Therapeutics Inc. (NASDAQ: RGLS) revealed top-line results from the primary endpoint analysis of one of its ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV). According to the company, the trial was meant to assess a shortened, four-week treatment regimen having a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29. This was in combination with 4 weeks of once/daily approved anti-viral agents Harvoni, Olysio, or Daklinza. Regulus Therapeutics said the trial enrolled 79 treatment naïve genotype 1 and 4 HCV patients (Harvoni ...Full story available on Benzinga.com
06/04/16 09:03 AMRegulus Therapeutics (RGLS) Adds New Board Member - StreetInsider.com
06/03/16 02:38 PMETF’s with exposure to Regulus Therapeutics, Inc. : June 3, 2016 -
06/03/16 09:01 AMShare Rating Focus on Regulus Therapeutics Inc. (NASDAQ:RGLS) - HNN - Share Rating Focus on Regulus Therapeutics Inc. (NASDAQ:RGLS)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 1 on shares of Regulus Therapeutics Inc. (NASDAQ:RGLS). Covering analysts will ...and more »
06/03/16 08:08 AMBiotech Industrys Stocks Get Research Review -
06/03/16 07:15 AMRegulus to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - LA JOLLA, Calif., June 3, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today ...
06/02/16 03:25 PMDr. Hugh Rosen Joins Regulus Board of Directors - [at noodls] - LA JOLLA, Calif., June 2, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), ...
06/02/16 09:07 AMTarget Price and Stock Performance Rundown for Regulus Therapeutics Inc. (NASDAQ:RGLS) - HNN - Target Price and Stock Performance Rundown for Regulus Therapeutics Inc. (NASDAQ:RGLS)HNNDuring the latest trading session, Regulus Therapeutics Inc. (NASDAQ:RGLS) shares traded -2.93%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
06/01/16 03:07 PMREGULUS THERAPEUTICS INC. Files SEC form 8-K, Other Events -
06/01/16 09:02 AMRegulus Therapeutics Expands Clinical Trial Collaboration With GSK - Regulus Therapeutics Inc. (RGLS) announced that it has expanded its clinical trial collaboration agreement with GSK (GSK) for the development of RG-101, Regulus' wholly-owned, GalNAc-conjugated anti-miR that targets miR-122. In the expanded collaboration ...
06/01/16 07:13 AMRegulus Expands Clinical Trial Collaboration with GSK - [at noodls] - LA JOLLA, Calif., June 1, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), ...
06/01/16 07:03 AM8:03 am Regulus Therapeutics expands clinical trial collaboration with GSK; ongoing Phase II RG-101 and oral GSK2878175 Combination Study on track to report interim results by year-end -
05/27/16 08:01 PMStock Rating Review for Regulus Therapeutics Inc. (NASDAQ:RGLS) - Wall Street Hints and News - Stock Rating Review for Regulus Therapeutics Inc. (NASDAQ:RGLS)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Regulus Therapeutics Inc. (NASDAQ:RGLS). Covering ...and more »
05/26/16 07:38 PMRa Capital Management LLC Decreased Stake in Regulus Therapeutics INC (NASDAQ:RGLS) by $14.63 Million as ... - CCH Daily News - Ra Capital Management LLC Decreased Stake in Regulus Therapeutics INC (NASDAQ:RGLS) by $14.63 Million as ...CCH Daily NewsPeter Kolchinsky decreased its stake in Regulus Therapeutics Inc (NASDAQ:RGLS) by 69.99% based on its latest 2016Q1 regulatory filing with the SEC. Ra Capital Management Llc sold 2.44M shares as the company's stock declined 19.14% while stock ...Insiders are Slowly Decreasing Positions in Regulus Therapeutics Inc. (NASDAQ:RGLS)The Postall 3 news articles »
05/26/16 01:55 AMTarget Check and Stock Performance Recap Regulus Therapeutics Inc. (NASDAQ:RGLS) - Wall Street Hints and News - Target Check and Stock Performance Recap Regulus Therapeutics Inc. (NASDAQ:RGLS)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Regulus Therapeutics Inc.and more »
05/26/16 01:55 AMBroker Roundup For Regulus Therapeutics Inc. (RGLS) - Share Trading News - Broker Roundup For Regulus Therapeutics Inc. (RGLS)Share Trading News04/15/2014 – Regulus Therapeutics Inc. was downgraded to “sell” by analysts at TheStreet. The share price of Regulus Therapeutics Inc. (RGLS) was up +2.63% during the last trading session, with a day high of 5.88. 530930 shares were traded on Regulus ...Regulus Therapeutics Inc. (NASDAQ:RGLS) Closes At $5.8500Investor Newswireall 2 news articles »
05/24/16 07:18 PMRegulus Therapeutics Inc. (NASDAQ:RGLS) One-Year Price Target At $22.67 - RealistInvestor.com - Regulus Therapeutics Inc. (NASDAQ:RGLS) One-Year Price Target At $22.67RealistInvestor.comFirst Call has set a 52-week price target of $22.67 on Regulus Therapeutics Inc. (NASDAQ:RGLS) stock after completion of its survey. For the approaching quarter, EPS estimate is set at $-0.38 and for underway fiscal at $-1.54. This estimate for next ...
05/23/16 07:16 AMRegulus Appoints Allison Wey as Vice President, Investor Relations & Corporate Communications - [at noodls] - LA JOLLA, Calif., May 23, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced ...
05/22/16 11:50 AMRegulus Therapeutics Inc. (NASDAQ:RGLS) One-Year Price Projection At $22.4 - Investor Newswire - Regulus Therapeutics Inc. (NASDAQ:RGLS) One-Year Price Projection At $22.4Investor NewswireSell-side analysts are certain on the prospect of Regulus Therapeutics Inc. (NASDAQ:RGLS) stock. As of 2016-05-21, the stock ABR stands at 1. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such ...and more »
05/21/16 06:37 PMRegulus Therapeutics (RGLS) Plans Presentation of New RG-012 at ERA-EDTA Congress - StreetInsider.com - Regulus Therapeutics (RGLS) Plans Presentation of New RG-012 at ERA-EDTA CongressStreetInsider.comRegulus Therapeutics Inc. (Nasdaq: RGLS) announced that new data on RG-012, the company's anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, ...and more »
05/20/16 07:04 PMAnalyst Rating Check on Regulus Therapeutics Inc. (NASDAQ:RGLS) - Wall Street Hints and News - Analyst Rating Check on Regulus Therapeutics Inc. (NASDAQ:RGLS)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 1 on shares of Regulus Therapeutics Inc. (NASDAQ:RGLS). Analysts that cover the ...and more »
05/20/16 07:04 PMNoticeable Buzzers: C.R. Bard, Inc. (NYSE:BCR) , Regulus Therapeutics Inc. (NASDAQ:RGLS) - Street Updates - News OracleNoticeable Buzzers: C.R. Bard, Inc. (NYSE:BCR) , Regulus Therapeutics Inc. (NASDAQ:RGLS)Street UpdatesRegulus Therapeutics Inc. (NASDAQ:RGLS) after beginning at $5.29, closed at $5.41 by building up +1.50% in recent trading session. Most recent session's volume of 837.72 thousand shares greater than its average volume of 776.66 thousand shares.Healthcare Stock seeking Investors: Regulus Therapeutics Inc (NASDAQ:RGLS)News OracleBroker Roundup For Regulus Therapeutics Inc. (RGLS)Share Trading NewsRegulus Therapeutics to Present New Data on Alport Syndrome Treatment RG Shares Up 2% (NASDAQ:RGLS)Sonoran Weekly ReviewStreetInsider.comall 6 news articles »
05/20/16 07:23 AMRegulus to Present New RG-012 Data at The 53rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress - [at noodls] - LA JOLLA, Calif., May 20, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today ...
05/18/16 07:07 PMRegulus Therapeutics Inc. (NASDAQ:RGLS) Quarterly EPS Projection At $-0.39 - Investor Newswire - Regulus Therapeutics Inc. (NASDAQ:RGLS) Quarterly EPS Projection At $-0.39Investor NewswireA week earlier, the EPS projection was $-0.39 while 30-days ago it was $-0.39. This target was set at $-0.39 60 days ago and it was $-0.39 90 days earlier. From a week ago, the change in estimates is 0%. EPS was revised 0 times up and 0 down in last ...and more »
About Regulus Therapeutics

Regulus Therapeutics logoRegulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Its development programs include microRNA target miR-122, miR-21, RG-012, miR-103/107, miR-19, miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs, RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RGLS
  • CUSIP: 75915K10
Key Metrics:
  • Previous Close: $5.29
  • 50 Day Moving Average: $5.59
  • 200 Day Moving Average: $6.72
  • P/E Ratio: N/A
  • P/E Growth: -0.09
  • Market Cap: $279.21M
  • Current Quarter EPS Consensus Estimate: $-1.54 EPS
Additional Links:
Regulus Therapeutics (NASDAQ:RGLS) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha